Related Experiment Video
Updated: Feb 19, 2026
Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
Published on: February 9, 2011
MOTS-c peptide increases survival and decreases bacterial load in mice infected with MRSA
Dongsheng Zhai1, Zichen Ye1, Yinghao Jiang1
1State Key Laboratory of Cancer Biology, Department of Pharmacogenomics, Fourth Military Medical University, Xi'an 710032, PR China.
Abstract:
Sepsis is a life-threatening disease characterized by uncontrolled inflammatory responses upon pathogen infections, especially for the antibiotic-resistant strains, such as Methicillin-resistant S. aureus (MRSA). Here we demonstrated that a Mitochondria-derived peptide (MOTS-c) could significantly improve the survival rate and decrease bacteria loads in MRSA-challenged mice, accompanied with declined levels of pro-inflammatory cytokines, such as TNF-α, IL-6 and IL-1β, but with increased level of anti-inflammatory cytokine IL-10. Moreover this peptide enhanced bactericidal capacity of macrophages. Meanwhile, MOTS-c inhibited the phosphorylation mitogen-activated protein kinases (MAPK), and enhanced the expression of aryl hydrocarbon receptor (AhR) and signal transducer and activator of transcriptional 3 (STAT3) in macrophages. Overall, MOTS-c plays a beneficial role in curbing the overwhelming inflammatory bursts in the fight against MRSA infection. It may serve as a potential therapeutic agent in sepsis treatment. Highlight.
Insights
Mitochondria-derived peptide (MOTS-c) shows promise in treating sepsis caused by Methicillin-resistant S. aureus (MRSA). This peptide improves survival rates and reduces inflammation, offering a potential new therapy for this life-threatening condition.
Area of Science:
- Immunology
- Molecular Biology
- Pharmacology
Background:
- Sepsis is a critical condition driven by uncontrolled inflammation, particularly concerning antibiotic-resistant bacteria like Methicillin-resistant S. aureus (MRSA).
- Current treatments face challenges against resistant pathogens, necessitating novel therapeutic strategies.
Purpose of the Study:
- To investigate the therapeutic potential of Mitochondria-derived peptide (MOTS-c) against MRSA-induced sepsis.
- To elucidate the molecular mechanisms underlying MOTS-c's effects on inflammatory responses and macrophage function.
Main Methods:
- Administration of MOTS-c to MRSA-challenged mice.
- Assessment of survival rates, bacterial load, cytokine levels (TNF-α, IL-6, IL-1β, IL-10), and macrophage bactericidal capacity.
- Analysis of MAPK phosphorylation, Aryl hydrocarbon receptor (AhR), and STAT3 expression in macrophages.
Main Results:
- MOTS-c significantly improved survival rates and reduced bacterial load in MRSA-infected mice.
- MOTS-c treatment led to decreased pro-inflammatory cytokines and increased anti-inflammatory cytokine IL-10.
- The peptide enhanced macrophage bactericidal activity, inhibited MAPK phosphorylation, and modulated AhR and STAT3 expression.
Conclusions:
- MOTS-c demonstrates a beneficial role in mitigating excessive inflammation during MRSA infection.
- MOTS-c exhibits potential as a novel therapeutic agent for sepsis treatment, particularly against resistant strains.
